Pasar al contenido principal

PROTEINAS DE FUSION BRD-NUT EN EL CARCINOMA DE LINEA MEDIA NUT: DEL DIAGNOSTICO AL TRATAMIENTO

PID2019-108008RJ-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer

  • Pascual-Reguant, Laura
  • Serra Camprubí, Queralt
  • Datta, Debayan
  • Cianferoni, Damiano
  • Kourtis, Savvas
  • Gañez-Zapater, Antoni|||0000-0002-6852-4834
  • Cannatá, Chiara|||0000-0003-4807-4669
  • Espinar, Lorena|||0000-0003-3881-3886
  • Querol, Jessica|||0000-0002-0527-759X
  • García-López, Laura
  • Musa-Afaneh, Sara
  • Guirola, Maria
  • Gkanogiannis, Anestis|||0000-0002-6441-0688
  • Miró Canturri, Andrea
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Herencia-Ropero, Andrea|||0009-0002-9448-1484
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Serra, Violeta|||0000-0001-6620-1065
  • Serrano, Luis|||0000-0002-5276-1392
  • Tian, Tian|||0000-0002-9906-0980
  • Peiró, Sandra|||0000-0001-9519-3877
  • Sdelci, Sara|||0000-0003-1330-4364
Triple-negative breast cancer (TNBC) often develops resistance to single-agent treatment, which can be circumvented using targeted combinatorial approaches. Here, we demonstrate that the simultaneous inhibition of LOXL2 and BRD4 synergistically limits TNBC proliferation in vitro and in vivo. Mechanistically, LOXL2 interacts in the nucleus with the short isoform of BRD4 (BRD4S), MED1, and the cell cycle transcriptional regulator B-MyB. These interactions sustain the formation of BRD4 and MED1 nuclear transcriptional foci and control cell cycle progression at the gene expression level. The pharmacological co-inhibition of LOXL2 and BRD4 reduces BRD4 nuclear foci, BRD4-MED1 colocalization, and the transcription of cell cycle genes, thus suppressing TNBC cell proliferation. Targeting the interaction between BRD4S and LOXL2 could be a starting point for the development of new anticancer strategies for the treatment of TNBC. Investigation of the molecular mechanisms underlying triple-negative breast cancer (TNBC) proliferation led to the identification of new therapeutic vulnerabilities.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer

  • Pascual-Reguant, Laura, 1990-
  • Datta, Debayan
  • Cianferoni, Damiano
  • Kourtis, Savvas
  • Gañez-Zapater, Antoni
  • Cannatá, Chiara
  • Espinar, Lorena
  • García López, Laura
  • Musa-Afaneh, Sara
  • Guirola, Maria
  • Gkanogiannis, Anestis
  • Miró Canturri, Andrea
  • Arribas, Joaquín
  • Serrano Pubull, Luis, 1982-
  • Sdelci, Sara
Triple-negative breast cancer (TNBC) often develops resistance to single-agent treatment, which can be circumvented using targeted combinatorial approaches. Here, we demonstrate that the simultaneous inhibition of LOXL2 and BRD4 synergistically limits TNBC proliferation in vitro and in vivo. Mechanistically, LOXL2 interacts in the nucleus with the short isoform of BRD4 (BRD4S), MED1, and the cell cycle transcriptional regulator B-MyB. These interactions sustain the formation of BRD4 and MED1 nuclear transcriptional foci and control cell cycle progression at the gene expression level. The pharmacological co-inhibition of LOXL2 and BRD4 reduces BRD4 nuclear foci, BRD4-MED1 colocalization, and the transcription of cell cycle genes, thus suppressing TNBC cell proliferation. Targeting the interaction between BRD4S and LOXL2 could be a starting point for the development of new anticancer strategies for the treatment of TNBC., We thank Pharmaxis for the supply of PXS LOXL2 inhibitors. SS is supported by the Plan Estatal de I + D + I (COMBAT PID2019‐110598GA‐I00), and the ERC Starting Grant (ERC‐StG‐852343‐EPICAMENTE). LP‐R is supported by the Juan de la Cierva‐Formación fellowship (FJC2019‐040598‐I) and Fundación Franscico Cobos fellowship. TVT is supported by Plan Estatal de I + D + I (PID2019‐108008RJ‐I00), AECC (INVES20036TIAN), and a Ramón y Cajal investigator contract (RYC2020‐029098‐I). DC is supported by the la Caixa Foundation PhD fellowship (ID 100010434; fellowship code LCF/BQ/DI19/11730061).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NADPH oxidase 1/4 dual inhibition impairs transforming growth factor-beta protumorigenic effects in cholangiocarcinoma cancer-associated fibroblasts

  • Amengual, Josep
  • Gonzalez-Sanchez, Ester
  • Yáñez-Bartolome, Mariana
  • Sererols-Viñas, Laura
  • Ravichandran, Sriram
  • Guiton, Celia
  • Fuste, Noel P.
  • Alay, Ania
  • Hijazo-Pechero, Sara
  • Martín-Mur, Beatriz
  • Gut, Marta
  • Esteve-Codina, Anna
  • Cantos-Cortes, Ana
  • Espinosa-Sotelo, Rut
  • Ramos, Emilio
  • Serrano, Teresa
  • Calvo, Mariona
  • Laquente, Berta
  • Ferrer, Joana
  • Pons, Gabriel
  • Mendez-Lucas, Andrés
  • Dooley, Steven
  • Ilyas, Sumera I.
  • Vallette, Marie
  • Aoudjehane, Lynda
  • Lequoy, Marie
  • Fouassier, Laura
  • Coulouarn, Cédric
  • Affò, Silvia
  • Scheiter, Alexander
  • Calvisi, Diego F.
  • Tian, Tian V.
  • Fabregat, Isabel
  • Vaquero, Javier
Transforming growth factor beta (TGF-β) signalling has become an attractive therapeutic target due to its pro-tumorigenic actions on epithelial cells and its immunosuppressive effects in the tumour microenvironment. In intrahepatic cholangiocarcinoma (iCCA), a highly aggressive malignancy of the biliary tract with poor prognosis, the latest clinical trials using TGF-β inhibitors have failed indicating that the specific actions carried out by TGF-β in iCCA are yet not well delineated. Here, we show that TGF-β signalling is highly active in iCCA and exerts a prominent suppressor effect on tumour cell lines and organoids established from iCCA metastases biopsies, that relies on a functional canonical SMAD2/3/4 signalling. Thus, TGF-β inhibitors promote, instead of inhibiting, tumour cell growth. In this context, a promising strategy is to target intracellular proteins downstream the TGF-β receptors accounting only for TGF-β pro-tumorigenic actions. NADPH oxidase 4 (NOX4), a downstream mediator of the TGF-β signalling pathway, is strictly expressed in cancer-associated fibroblasts (CAF) of iCCA and acts in concert with NOX1 to regulate CAF functions. Use of a dual NOX4/NOX1 inhibitor impaired CAF actions and reduced tumour growth in vitro and in two different in vivo iCCA experimental models. Collectively, our findings reveal an actionable way to specifically target TGF-β pro-tumorigenic actions in CAF from iCCA without undesirable side effects on tumour cells, suggesting a potentially bright future for dual NOX4/NOX1 inhibitors in the clinics, alone or in combination with other therapies., This work was supported by (i) Spanish Association for Cancer Research (AECC), Spain, grant #PRYGN211279FABR, to I.F.; (ii) Agencia Estatal de Investigación (AEI), Ministry of Science and Innovation (MICIN), Spain, cofounded by FEDER funds/Development Fund—a way to build Europe, grant numbers #RTI2018-094079-B-100, #RTC2019-007125-1, to I.F.; #PID2019-108651RJ-I00, PID2022-141984OB-I00 and RYC2021-034121-I, to J.V. J.V. was funded by AEI, MICIN, through the Retos Investigación grant number PID2019-108651RJ-I00/DOI 10.13039/501100011033 and “Ramon y Cajal” program RYC2021-034121-I. The CIBEREHD, National Biomedical Research Institute on Liver and Gastrointestinal Diseases, is funded by the Instituto de Salud Carlos III, Spain. We thank the CERCA Programme/Generalitat de Catalunya for institutional support. Institutional support to CNAG was provided by the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III, and by the Generalitat de Catalunya through the Departament de Salut and the Departament de Recerca i Universitats. C.C. is supported by Inserm, Université de Rennes, Ligue Contre le Cancer (R23037NN), INCa (EU TRANSCAN23-002-2023-129, INCa_18688, R21251ND), ITMO Cancer of AVIESAN within the framework of the 2021-2030 Cancer Control Strategy, on funds administered by Inserm (C18007NS, C20013NS, C20014NS), the French Ministry of Health and the French National Cancer Institute (PRT-K20-136). T.V.T. was supported by grants from the Spanish Ministry of Science, Innovation and University (PID2019-108008RJ-I00, PID2023-146827OB-I00), Fundació La Marató TV3 (201931-31), and “Ramon y Cajal” program (RYC2020-029098-I). L.F. received financial support from the “Ligue contre le cancer” (RS24/75-62) and from ITMO Cancer of Aviesan on funds administered by Inserm (C21044DS/ ASC21044DSA). S.A. is supported by PID2021-124694OA-I00, MCIN/AEI/ 10.13039/501100011033 and FEDER Una manera de hacer Europa, The European Union grant agreement 101077312* and Ramon y Cajal program RYC2022-036321-I. *, Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation

  • Serra Camprubi, Queralt
  • Verdaguer Mata, Helena
  • Oliveros, Winona
  • Lupión-Garcia, Núria
  • Llop Guevara, Alba
  • Vila Casadesus, Maria
  • Querol Paños, Jessica
  • Nuciforo, Paolo Giovanni
  • Vivancos Prellezo, Ana
  • Serra Elizalde, Violeta
  • Arribas López, Joaquin Vicente
  • Tabernero, Josep
  • Peiro Sales, Sandra
  • Tian, Tian V
  • Bernadó Morales, Cristina
  • Arenas Lahuerta, Enrique Javier
  • Frigola Rissech, Joan
  • Fabregat Franco, Carles
  • Castet, Florian
  • Miquel Aymar, Josep Maria
  • Escudero Iriarte, Carmen
  • Yáñez, Mariana
  • Escorihuela Baez, Marta
  • Macarulla Mercadé, Teresa
  • Molina, Cristina
Human metastatic cholangiocarcinoma; Xenografts; Tumoroids, Colangiocarcinoma metastàtic humà; Xenoempelts; Tumoroides, Colangiocarcinoma metastásico humano; Xenoinjertos; Tumoroides, Purpose: Cholangiocarcinoma (CCA) is usually diagnosed at advanced stages, with limited therapeutic options. Preclinical models focused on unresectable metastatic CCA are necessary to develop rational treatments. Pathogenic mutations in IDH1/2, ARID1A/B, BAP1, and BRCA1/2 have been identified in 30%–50% of patients with CCA. Several types of tumor cells harboring these mutations exhibit homologous recombination deficiency (HRD) phenotype with enhanced sensitivity to PARP inhibitors (PARPi). However, PARPi treatment has not yet been tested for effectiveness in patient-derived models of advanced CCA. Experimental Design: We have established a collection of patient-derived xenografts from patients with unresectable metastatic CCA (CCA_PDX). The CCA_PDXs were characterized at both histopathologic and genomic levels. We optimized a protocol to generate CCA tumoroids from CCA_PDXs. We tested the effects of PARPis in both CCA tumoroids and CCA_PDXs. Finally, we used the RAD51 assay to evaluate the HRD status of CCA tissues. Results: This collection of CCA_PDXs recapitulates the histopathologic and molecular features of their original tumors. PARPi treatments inhibited the growth of CCA tumoroids and CCA_PDXs with pathogenic mutations of BRCA2, but not those with mutations of IDH1, ARID1A, or BAP1. In line with these findings, only CCA_PDX and CCA patient biopsy samples with mutations of BRCA2 showed RAD51 scores compatible with HRD. Conclusions: Our results suggest that patients with advanced CCA with pathogenic mutations of BRCA2, but not those with mutations of IDH1, ARID1A, or BAP1, are likely to benefit from PARPi therapy. This collection of CCA_PDXs provides new opportunities for evaluating drug response and prioritizing clinical trials., This work was supported by grants from the Fundació Marató TV3 awarded to T. Macarulla, M. Melé, and S. Peiró; BeiGene research grant awarded to T. Macarulla and S. Peiró; AECC (INVES20036TIAN), Ramón y Cajal investigator program (RYC2020-029098-I), Proyecto de I+D+i (PID2019-108008RJ-I00), and FERO Foundation grant awarded to T.V. Tian; Proyecto de Investigación en Salud from the Instituto de Salud Carlos III (ISCIII) (PI20/00898) awarded to T. Macarulla; FIS/FEDER from the Instituto de Salud Carlos III (ISCIII) (PI12/01250; CP08/00223; PI16/00253 and CB16/12/00449) awarded to S. Peiró; and Ramón y Cajal investigator program (RYC-2017-22249) awarded to M. Melé. Q. Serra-Camprubí is a recipient of the Ph.D. fellowship from La Caixa Foundation (LCF/PR/PR12/51070001). A. Llop-Guevara was supported by the AECC (INVES20095LLOP) and V. Serra by the ISCIII (CPII19/00033). E.J. Arenas was funded by the AECC (POSTD211413AREN). J. Arribas is funded by the Instituto de Salud Carlos III (AC15/00062, CB16/12/00449, and PI22/00001). This publication is based upon the work of COST Action CA18122, European Cholangiocarcinoma Network, supported by the COST (European Cooperation in Science and Technology, www.cost.eu), a funding agency for research and innovation networks. The authors would like to thank Dr. V.A. Raker for manuscript editing and Drs. N. Herranz and J. Mateo for scientific discussions. The authors acknowledge the infrastructure and support of the FERO Foundation, La Caixa Foundation, and the Cellex Foundation.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor

  • Turpin, Anthony
  • Delliaux, Carine
  • Pauline, PARENT
  • Chevalier, Hortense
  • Escudero Iriarte, Carmen
  • Bonardi, Franck
  • Querol, Jessica
  • Herranz Martín, Nicolás
  • TIAN, TIAN
Endocrine cancer, Càncer endocrí, Cáncer endocrino, Background Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer, arising from resistance to androgen-deprivation therapies. However, the molecular mechanisms associated with NEPC development and invasiveness are still poorly understood. Here we investigated the expression and functional significance of Fascin-1 (FSCN1), a pro-metastasis actin-bundling protein associated with poor prognosis of several cancers, in neuroendocrine differentiation of prostate cancer. Methods Differential expression analyses using Genome Expression Omnibus (GEO) database, clinical samples and cell lines were performed. Androgen or antagonist’s cellular treatments and knockdown experiments were used to detect changes in cell morphology, molecular markers, migration properties and in vivo tumour growth. Chromatin immunoprecipitation-sequencing (ChIP-Seq) data and ChIP assays were analysed to decipher androgen receptor (AR) binding. Results We demonstrated that FSCN1 is upregulated during neuroendocrine differentiation of prostate cancer in vitro, leading to phenotypic changes and NEPC marker expression. In human prostate cancer samples, FSCN1 expression is restricted to NEPC tumours. We showed that the androgen-activated AR downregulates FSCN1 expression and works as a transcriptional repressor to directly suppress FSCN1 expression. AR antagonists alleviate this repression. In addition, FSCN1 silencing further impairs in vivo tumour growth. Conclusion Collectively, our findings identify FSCN1 as an AR-repressed gene. Particularly, it is involved in NEPC aggressiveness. Our results provide the rationale for the future clinical development of FSCN1 inhibitors in NEPC patients., This work was funded by CNRS (Centre national de recherche scientifique), INSERM (Institut national de la santé et de la recherche médicale), Université de Lille, Institut Pasteur de Lille, and supported by grants from Ligue nationale contre le Cancer (Comité de l’Aisne), Institut national du cancer (INCa_4419), ARTP (Association de Recherche sur les tumeurs de prostate). This work is supported by a grant from Contrat de Plan Etat-Région CPER Cancer 2015–2020. Work performed at the laboratory of TVT was supported by Spanish Plan Estatal de I + D + I (PID2019-108008RJ-I00), AECC (INVES20036TIAN), Ramón y Cajal investigator programme (RYC2020-029098-I), and FERO Foundation. CD was supported by Institut Pasteur de Lille, Conseil Régional des Hauts-de-France and Fondation pour la Recherche Médicale (FRM).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The potential of patient-derived organoids in precision medicine of biliary tract cancer

  • Yáñez, Mariana
  • TIAN, TIAN
  • Macarulla, Teresa
Organoids; Precision; Biliary tract cancer, Organoides; Medicina de precisión; Cáncer de vías biliares, Organoides; Medicina de precisió; Càncer de vies biliars, Chemotherapy resistance in biliary tract cancer (BTC) presents a major clinical hurdle. Ren et al.1 developed and characterized an extensive collection of BTC patient-derived organoid (PDO) models, enabling advanced investigation of chemotherapy response prediction., This work is supported by grants from the EU Transcan-3 project (SIMMBAP), Instituto de Salud Carlos III (PMP22/00054 and PI20/00898) awarded to T.M., and grants from Asociación Española Contra el Cáncer (AECC), Ministerio de Ciencia e Innovación de España (RYC2020-029098-I and PID2019-108008RJ-I00), and FERO Foundation awarded to T.V.T.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple‐negative breast cancer

  • Pascual Reguant, Laura
  • Serra Camprubí, Queralt
  • Datta, Debayan
  • Cianferoni, Damiano
  • Kourtis, Savvas
  • Gañez Zapater, Antoni
  • Miró Canturri, Andrea
  • Guzman Torres, Marta
  • Rodríguez, Olga
  • Querol, Jessica
  • Herencia Ropero, Andrea
  • Arribas, Joaquin
  • TIAN, TIAN
  • Peiró, Sandra
  • Serra, Violeta
Cell cycle; Gene expression; Triple-negative breast cancer, Ciclo celular; Expresión génica; Cáncer de mama triple negativo, Cicle cel·lular; Expressió gènica; Càncer de mama triple negatiu, Triple‐negative breast cancer (TNBC) often develops resistance to single‐agent treatment, which can be circumvented using targeted combinatorial approaches. Here, we demonstrate that the simultaneous inhibition of LOXL2 and BRD4 synergistically limits TNBC proliferation in vitro and in vivo. Mechanistically, LOXL2 interacts in the nucleus with the short isoform of BRD4 (BRD4S), MED1, and the cell cycle transcriptional regulator B‐MyB. These interactions sustain the formation of BRD4 and MED1 nuclear transcriptional foci and control cell cycle progression at the gene expression level. The pharmacological co‐inhibition of LOXL2 and BRD4 reduces BRD4 nuclear foci, BRD4‐MED1 colocalization, and the transcription of cell cycle genes, thus suppressing TNBC cell proliferation. Targeting the interaction between BRD4S and LOXL2 could be a starting point for the development of new anticancer strategies for the treatment of TNBC., We thank the CRG genomics unit, the CRG‐UPF flow cytometry unit, and the VHIO mouse facility for their contribution. We thank Pharmaxis for the supply of PXS LOXL2 inhibitors. SS is supported by the Plan Estatal de I + D + I (COMBAT PID2019‐110598GA‐I00), and the ERC Starting Grant (ERC‐StG‐852343‐EPICAMENTE). LP‐R is supported by the Juan de la Cierva‐Formación fellowship (FJC2019‐040598‐I) and Fundación Franscico Cobos fellowship. TVT is supported by Plan Estatal de I + D + I (PID2019‐108008RJ‐I00), AECC (INVES20036TIAN), and a Ramón y Cajal investigator contract (RYC2020‐029098‐I). DC is supported by the la Caixa Foundation PhD fellowship (ID 100010434; fellowship code LCF/BQ/DI19/11730061).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer

  • Pascual-Reguant, Laura, 1990-
  • Datta, Debayan
  • Cianferoni, Damiano
  • Kourtis, Savvas
  • Gañez-Zapater, Antoni
  • Cannatá, Chiara
  • Espinar, Lorena
  • García López, Laura
  • Musa-Afaneh, Sara
  • Guirola, Maria
  • Gkanogiannis, Anestis
  • Miró Canturri, Andrea
  • Arribas, Joaquín
  • Serrano Pubull, Luis, 1982-
  • Sdelci, Sara
Triple-negative breast cancer (TNBC) often develops resistance to single-agent treatment, which can be circumvented using targeted combinatorial approaches. Here, we demonstrate that the simultaneous inhibition of LOXL2 and BRD4 synergistically limits TNBC proliferation in vitro and in vivo. Mechanistically, LOXL2 interacts in the nucleus with the short isoform of BRD4 (BRD4S), MED1, and the cell cycle transcriptional regulator B-MyB. These interactions sustain the formation of BRD4 and MED1 nuclear transcriptional foci and control cell cycle progression at the gene expression level. The pharmacological co-inhibition of LOXL2 and BRD4 reduces BRD4 nuclear foci, BRD4-MED1 colocalization, and the transcription of cell cycle genes, thus suppressing TNBC cell proliferation. Targeting the interaction between BRD4S and LOXL2 could be a starting point for the development of new anticancer strategies for the treatment of TNBC., We thank Pharmaxis for the supply of PXS LOXL2 inhibitors. SS is supported by the Plan Estatal de I + D + I (COMBAT PID2019‐110598GA‐I00), and the ERC Starting Grant (ERC‐StG‐852343‐EPICAMENTE). LP‐R is supported by the Juan de la Cierva‐Formación fellowship (FJC2019‐040598‐I) and Fundación Franscico Cobos fellowship. TVT is supported by Plan Estatal de I + D + I (PID2019‐108008RJ‐I00), AECC (INVES20036TIAN), and a Ramón y Cajal investigator contract (RYC2020‐029098‐I). DC is supported by the la Caixa Foundation PhD fellowship (ID 100010434; fellowship code LCF/BQ/DI19/11730061).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The potential of patient-derived organoids in precision medicine of biliary tract cancer

  • Yáñez, Mariana
  • TIAN, TIAN
  • Macarulla, Teresa
Organoids; Precision; Biliary tract cancer, Organoides; Medicina de precisión; Cáncer de vías biliares, Organoides; Medicina de precisió; Càncer de vies biliars, Chemotherapy resistance in biliary tract cancer (BTC) presents a major clinical hurdle. Ren et al.1 developed and characterized an extensive collection of BTC patient-derived organoid (PDO) models, enabling advanced investigation of chemotherapy response prediction., This work is supported by grants from the EU Transcan-3 project (SIMMBAP), Instituto de Salud Carlos III (PMP22/00054 and PI20/00898) awarded to T.M., and grants from Asociación Española Contra el Cáncer (AECC), Ministerio de Ciencia e Innovación de España (RYC2020-029098-I and PID2019-108008RJ-I00), and FERO Foundation awarded to T.V.T.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple‐negative breast cancer

  • Pascual Reguant, Laura
  • Serra Camprubí, Queralt
  • Datta, Debayan
  • Cianferoni, Damiano
  • Kourtis, Savvas
  • Gañez Zapater, Antoni
  • Miró Canturri, Andrea
  • Guzman Torres, Marta
  • Rodríguez, Olga
  • Querol, Jessica
  • Herencia Ropero, Andrea
  • Arribas, Joaquin
  • TIAN, TIAN
  • Peiró, Sandra
  • Serra, Violeta
Cell cycle; Gene expression; Triple-negative breast cancer, Ciclo celular; Expresión génica; Cáncer de mama triple negativo, Cicle cel·lular; Expressió gènica; Càncer de mama triple negatiu, Triple‐negative breast cancer (TNBC) often develops resistance to single‐agent treatment, which can be circumvented using targeted combinatorial approaches. Here, we demonstrate that the simultaneous inhibition of LOXL2 and BRD4 synergistically limits TNBC proliferation in vitro and in vivo. Mechanistically, LOXL2 interacts in the nucleus with the short isoform of BRD4 (BRD4S), MED1, and the cell cycle transcriptional regulator B‐MyB. These interactions sustain the formation of BRD4 and MED1 nuclear transcriptional foci and control cell cycle progression at the gene expression level. The pharmacological co‐inhibition of LOXL2 and BRD4 reduces BRD4 nuclear foci, BRD4‐MED1 colocalization, and the transcription of cell cycle genes, thus suppressing TNBC cell proliferation. Targeting the interaction between BRD4S and LOXL2 could be a starting point for the development of new anticancer strategies for the treatment of TNBC., We thank the CRG genomics unit, the CRG‐UPF flow cytometry unit, and the VHIO mouse facility for their contribution. We thank Pharmaxis for the supply of PXS LOXL2 inhibitors. SS is supported by the Plan Estatal de I + D + I (COMBAT PID2019‐110598GA‐I00), and the ERC Starting Grant (ERC‐StG‐852343‐EPICAMENTE). LP‐R is supported by the Juan de la Cierva‐Formación fellowship (FJC2019‐040598‐I) and Fundación Franscico Cobos fellowship. TVT is supported by Plan Estatal de I + D + I (PID2019‐108008RJ‐I00), AECC (INVES20036TIAN), and a Ramón y Cajal investigator contract (RYC2020‐029098‐I). DC is supported by the la Caixa Foundation PhD fellowship (ID 100010434; fellowship code LCF/BQ/DI19/11730061).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation

  • Serra Camprubi, Queralt
  • Verdaguer Mata, Helena
  • Oliveros, Winona
  • Lupión-Garcia, Núria
  • Llop Guevara, Alba
  • Vila Casadesus, Maria
  • Querol Paños, Jessica
  • Nuciforo, Paolo Giovanni
  • Vivancos Prellezo, Ana
  • Serra Elizalde, Violeta
  • Arribas López, Joaquin Vicente
  • Tabernero, Josep
  • Peiro Sales, Sandra
  • Tian, Tian V
  • Bernadó Morales, Cristina
  • Arenas Lahuerta, Enrique Javier
  • Frigola Rissech, Joan
  • Fabregat Franco, Carles
  • Castet, Florian
  • Miquel Aymar, Josep Maria
  • Escudero Iriarte, Carmen
  • Yáñez, Mariana
  • Escorihuela Baez, Marta
  • Macarulla Mercadé, Teresa
  • Molina, Cristina
Human metastatic cholangiocarcinoma; Xenografts; Tumoroids, Colangiocarcinoma metastàtic humà; Xenoempelts; Tumoroides, Colangiocarcinoma metastásico humano; Xenoinjertos; Tumoroides, Purpose: Cholangiocarcinoma (CCA) is usually diagnosed at advanced stages, with limited therapeutic options. Preclinical models focused on unresectable metastatic CCA are necessary to develop rational treatments. Pathogenic mutations in IDH1/2, ARID1A/B, BAP1, and BRCA1/2 have been identified in 30%–50% of patients with CCA. Several types of tumor cells harboring these mutations exhibit homologous recombination deficiency (HRD) phenotype with enhanced sensitivity to PARP inhibitors (PARPi). However, PARPi treatment has not yet been tested for effectiveness in patient-derived models of advanced CCA. Experimental Design: We have established a collection of patient-derived xenografts from patients with unresectable metastatic CCA (CCA_PDX). The CCA_PDXs were characterized at both histopathologic and genomic levels. We optimized a protocol to generate CCA tumoroids from CCA_PDXs. We tested the effects of PARPis in both CCA tumoroids and CCA_PDXs. Finally, we used the RAD51 assay to evaluate the HRD status of CCA tissues. Results: This collection of CCA_PDXs recapitulates the histopathologic and molecular features of their original tumors. PARPi treatments inhibited the growth of CCA tumoroids and CCA_PDXs with pathogenic mutations of BRCA2, but not those with mutations of IDH1, ARID1A, or BAP1. In line with these findings, only CCA_PDX and CCA patient biopsy samples with mutations of BRCA2 showed RAD51 scores compatible with HRD. Conclusions: Our results suggest that patients with advanced CCA with pathogenic mutations of BRCA2, but not those with mutations of IDH1, ARID1A, or BAP1, are likely to benefit from PARPi therapy. This collection of CCA_PDXs provides new opportunities for evaluating drug response and prioritizing clinical trials., This work was supported by grants from the Fundació Marató TV3 awarded to T. Macarulla, M. Melé, and S. Peiró; BeiGene research grant awarded to T. Macarulla and S. Peiró; AECC (INVES20036TIAN), Ramón y Cajal investigator program (RYC2020-029098-I), Proyecto de I+D+i (PID2019-108008RJ-I00), and FERO Foundation grant awarded to T.V. Tian; Proyecto de Investigación en Salud from the Instituto de Salud Carlos III (ISCIII) (PI20/00898) awarded to T. Macarulla; FIS/FEDER from the Instituto de Salud Carlos III (ISCIII) (PI12/01250; CP08/00223; PI16/00253 and CB16/12/00449) awarded to S. Peiró; and Ramón y Cajal investigator program (RYC-2017-22249) awarded to M. Melé. Q. Serra-Camprubí is a recipient of the Ph.D. fellowship from La Caixa Foundation (LCF/PR/PR12/51070001). A. Llop-Guevara was supported by the AECC (INVES20095LLOP) and V. Serra by the ISCIII (CPII19/00033). E.J. Arenas was funded by the AECC (POSTD211413AREN). J. Arribas is funded by the Instituto de Salud Carlos III (AC15/00062, CB16/12/00449, and PI22/00001). This publication is based upon the work of COST Action CA18122, European Cholangiocarcinoma Network, supported by the COST (European Cooperation in Science and Technology, www.cost.eu), a funding agency for research and innovation networks. The authors would like to thank Dr. V.A. Raker for manuscript editing and Drs. N. Herranz and J. Mateo for scientific discussions. The authors acknowledge the infrastructure and support of the FERO Foundation, La Caixa Foundation, and the Cellex Foundation.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor

  • Turpin, Anthony
  • Delliaux, Carine
  • Pauline, PARENT
  • Chevalier, Hortense
  • Escudero Iriarte, Carmen
  • Bonardi, Franck
  • Querol, Jessica
  • Herranz Martín, Nicolás
  • TIAN, TIAN
Endocrine cancer, Càncer endocrí, Cáncer endocrino, Background Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer, arising from resistance to androgen-deprivation therapies. However, the molecular mechanisms associated with NEPC development and invasiveness are still poorly understood. Here we investigated the expression and functional significance of Fascin-1 (FSCN1), a pro-metastasis actin-bundling protein associated with poor prognosis of several cancers, in neuroendocrine differentiation of prostate cancer. Methods Differential expression analyses using Genome Expression Omnibus (GEO) database, clinical samples and cell lines were performed. Androgen or antagonist’s cellular treatments and knockdown experiments were used to detect changes in cell morphology, molecular markers, migration properties and in vivo tumour growth. Chromatin immunoprecipitation-sequencing (ChIP-Seq) data and ChIP assays were analysed to decipher androgen receptor (AR) binding. Results We demonstrated that FSCN1 is upregulated during neuroendocrine differentiation of prostate cancer in vitro, leading to phenotypic changes and NEPC marker expression. In human prostate cancer samples, FSCN1 expression is restricted to NEPC tumours. We showed that the androgen-activated AR downregulates FSCN1 expression and works as a transcriptional repressor to directly suppress FSCN1 expression. AR antagonists alleviate this repression. In addition, FSCN1 silencing further impairs in vivo tumour growth. Conclusion Collectively, our findings identify FSCN1 as an AR-repressed gene. Particularly, it is involved in NEPC aggressiveness. Our results provide the rationale for the future clinical development of FSCN1 inhibitors in NEPC patients., This work was funded by CNRS (Centre national de recherche scientifique), INSERM (Institut national de la santé et de la recherche médicale), Université de Lille, Institut Pasteur de Lille, and supported by grants from Ligue nationale contre le Cancer (Comité de l’Aisne), Institut national du cancer (INCa_4419), ARTP (Association de Recherche sur les tumeurs de prostate). This work is supported by a grant from Contrat de Plan Etat-Région CPER Cancer 2015–2020. Work performed at the laboratory of TVT was supported by Spanish Plan Estatal de I + D + I (PID2019-108008RJ-I00), AECC (INVES20036TIAN), Ramón y Cajal investigator programme (RYC2020-029098-I), and FERO Foundation. CD was supported by Institut Pasteur de Lille, Conseil Régional des Hauts-de-France and Fondation pour la Recherche Médicale (FRM).